CG Oncology (NASDAQ: CGON) recently received a number of ratings updates from brokerages and research firms:
- 11/17/2026 – CG Oncology was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $97.00 price target on the stock, up from $80.00.
- 11/17/2026 – CG Oncology had its price target raised by Wedbush from $84.00 to $91.00. They now have an “outperform” rating on the stock.
- 11/17/2026 – CG Oncology had its price target raised by HC Wainwright from $100.00 to $115.00. They now have a “buy” rating on the stock.
- 11/9/2026 – CG Oncology had its price target lowered by Guggenheim from $90.00 to $89.00. They now have a “buy” rating on the stock.
- 11/7/2026 – CG Oncology was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 11/6/2026 – CG Oncology had its price target raised by Wedbush from $80.00 to $84.00. They now have an “outperform” rating on the stock.
- 10/15/2026 – CG Oncology had its “sell (d-)” rating reaffirmed by Weiss Ratings.
CG Oncology Trading Up 14.0%
Shares of CG Oncology stock opened at $84.78 on Tuesday. CG Oncology, Inc. has a 12-month low of $37.01 and a 12-month high of $93.95. The stock has a market cap of $7.57 billion, a PE ratio of -30.72 and a beta of 0.35. The company has a 50-day moving average of $68.24 and a two-hundred day moving average of $66.70.
CG Oncology (NASDAQ:CGON – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. On average, sell-side analysts forecast that CG Oncology, Inc. will post -3.00 EPS for the current fiscal year.
Insider Buying and Selling at CG Oncology
In related news, Director Leonard E. Post sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $62.06, for a total value of $62,060.00. Following the completion of the transaction, the director directly owned 1,000 shares of the company’s stock, valued at $62,060. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.80% of the stock is currently owned by corporate insiders.
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-GuĂ©rin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Read More
- Five stocks we like better than CG Oncology
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for CG Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.
